A Phase 1, Open-Label, Multiple-Dose, Dose Escalation Study of the Safety and Tolerability of Staphylococcal Protein A in Adult Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Contacts and Locations

A Phase 1, Open-Label, Multiple-Dose, Dose Escalation Study of the Safety and Tolerability of Staphylococcal Protein A in Adult Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

This study is currently recruiting participants.

Study NCT00571467. Last updated on May 1, 2008. Information provided by Protalex, Inc.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00571467

Contacts


Contact: Edward Bernton, MD		ebernton@protalex.com

Locations


Australia, Australian Capital Territory
	Canberra Hospital	Recruiting
	Garran, Australian Capital Territory, Australia

Australia, New South Wales
	St. George Hospital	Recruiting
	Sydney, New South Wales, Australia

Australia, Queensland
	Royal Brisbane	Recruiting
	Brisbane, Queensland, Australia

Australia, Victoria
	Monash Medical Centre	Recruiting
	Melbourne, Victoria, Australia

Australia, Western Australia
	Freemantle Hospital	Recruiting
	Freemantle, Western Australia, Australia
	Royal Perth Hospital	Recruiting
	Perth, Western Australia, Australia

New Zealand, Auckland
	Middlemore Hospital	Recruiting
	Otahuhu, Auckland, New Zealand

Sponsors and Collaborators

Protalex, Inc.

Investigators


Study Director:	Edward Bernton, MD	Protalex, Inc.